{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"ZWCCSIUBHCZKOY-UHFFFAOYSA-N","prefName":"ADB-CHMINACA (MAB-CHMINACA)","symbol":"ADB-CHMINACA","iupacName":"N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide","aliases":["MAB-CHMINACA"],"cas":"1863065-92-2","pubchemCid":"77565944","chebiId":null,"smiles":"CC(C)(C)C(C(=O)N)NC(=O)C1=NN(C2=CC=CC=C21)CC3CCCCC3","molecularFormula":"C21H30N4O2","molecularWeight":370.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/77565944"}},"classification":{"family":"scra","familyLabel":"Cannabinoide sintético (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origen (investigación farmacéutica → mercado ilícito)","summaryFr":"Ninguna vía biológica: molécula enteramente sintética de la clase de las indazol-3-carboxamidas, formada por acoplamiento amídico entre un ácido indazol-3-carboxílico N-alquilado con un grupo ciclohexilmetilo y una tert-leucinamida. No la produce ninguna planta y no deriva del cannabigerol.","originNote":"Laboratorio (cannabinoide de síntesis, ausente del cáñamo)","discovered":""},"pharmacology":{"summaryFr":"El ADB-CHMINACA es un agonista sintético de los receptores cannabinoides de la familia de las indazol-3-carboxamidas, descrito en 2009 en una patente de Pfizer antes de aparecer en el mercado de las nuevas sustancias psicoactivas en 2014. La literatura le atribuye una afinidad muy elevada por el receptor CB1, Ki = 0,289 nM, asociada a una eficacia de agonista completo, allí donde el Δ9-THC sigue siendo un agonista parcial: es esta combinación, y no una simple cuestión de dosis, la que explica la gravedad de los cuadros clínicos observados. En el roedor, la sustancia sustituye por completo al Δ9-THC en una prueba de discriminación, efecto antagonizado por el rimonabant. Se comunica una actividad en el receptor CB2, pero las constantes publicadas siguen siendo escasas. Faltan por completo los datos humanos controlados: no existe ningún estudio de farmacología clínica, y todo lo que se conoce en el ser humano procede de series de intoxicaciones y de análisis médico-legales.","receptorSummaryFr":"Agonista completo del receptor CB1, con una afinidad comunicada en la literatura de Ki = 0,289 nM, muy superior a la del Δ9-THC, que no es más que un agonista parcial. En las revisiones de síntesis se describe una actividad agonista en el receptor CB2, sin constante ampliamente reproducida. En la rata, la sustancia sustituye por completo al Δ9-THC en una prueba de discriminación y ese efecto queda bloqueado por el rimonabant, lo que confirma una mediación por CB1. Ningún dato publicado documenta una acción sobre TRPV1, GPR55, PPARγ o 5-HT1A.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":98,"reported":"Ki = 0,289 nM (CB1), efficacité d'agoniste complet","confidence":"medium"},{"target":"CB2","efficacy":"full_agonist","relativeActivity":70,"reported":null,"confidence":"low"}],"references":[{"label":"Carlier J et al. Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS J, 2017.","pmid":"28070717","doi":"10.1208/s12248-016-0037-5","url":"https://pubmed.ncbi.nlm.nih.gov/28070717/"},{"label":"Adamowicz P, Gieroń J. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA. Clinical Toxicology, 2016.","pmid":"27227269","doi":"10.1080/15563650.2016.1190016","url":"https://pubmed.ncbi.nlm.nih.gov/27227269/"},{"label":"Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015). Clinical Toxicology, 2019.","pmid":"29989463","doi":"10.1080/15563650.2018.1485927","url":"https://pubmed.ncbi.nlm.nih.gov/29989463/"},{"label":"Hermanns-Clausen M et al. Acute toxicity of ADB-CHMINACA: a case series of patients with pronounced central nervous symptoms. British Journal of Clinical Pharmacology, 2026.","pmid":"41916726","doi":"10.1002/bcp.70538","url":"https://pubmed.ncbi.nlm.nih.gov/41916726/"},{"label":"Gatch MB, Forster MJ. Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats. Psychopharmacology, 2018.","pmid":"29138877","doi":"10.1007/s00213-017-4783-6","url":"https://pubmed.ncbi.nlm.nih.gov/29138877/"},{"label":"Hasegawa K et al. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. Forensic Toxicology, 2015.","pmid":"26257834","doi":"10.1007/s11419-015-0272-y","url":"https://pubmed.ncbi.nlm.nih.gov/26257834/"},{"label":"Hasegawa K et al. Identification and quantification of predominant metabolites of MAB-CHMINACA in an authentic human urine specimen. Drug Testing and Analysis, 2018.","pmid":"28560823","doi":"10.1002/dta.2220","url":"https://pubmed.ncbi.nlm.nih.gov/28560823/"},{"label":"Wouters E et al. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists. Drug Testing and Analysis, 2019.","pmid":"31021521","doi":"10.1002/dta.2607","url":"https://pubmed.ncbi.nlm.nih.gov/31021521/"},{"label":"Navarro-Tapia E et al. Detection of the Synthetic Cannabinoids AB-CHMINACA, ADB-CHMINACA, MDMB-CHMICA and 5F-MDMB-PINACA in Biological Matrices: A Systematic Review. Biology, 2022.","pmid":"35625524","doi":"10.3390/biology11050796","url":"https://pubmed.ncbi.nlm.nih.gov/35625524/"},{"label":"Filipiuc SI et al. Acute Toxicity of Three Synthetic Cannabinoids: First In Vivo Preclinical Study. Molecules, 2026.","pmid":"42451732","doi":"10.3390/molecules31132365","url":"https://pubmed.ncbi.nlm.nih.gov/42451732/"},{"label":"OICS, Liste verte : substances psychotropes sous contrôle international (ADB-CHMINACA, tableau II, code PC 013)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/en/psychotropics/green-list.html"},{"label":"OFDT, Nouveaux produits de synthèse : cadre légal français des cannabinoïdes de synthèse (arrêté du 31 mars 2017)","pmid":null,"doi":null,"url":"https://www.ofdt.fr/produits-et-addictions/de-z/nouveaux-produits-de-synthese/"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calma","description":"Relajación del cuerpo y de la mente; menos ruido mental, sin somnolencia marcada.","intensity":10},{"key":"focus","label":"Claridad","description":"Atención sostenida y pensamiento claro; lucidez funcional, sin euforia.","intensity":5},{"key":"sleep","label":"Sueño","description":"Efecto sedante: favorece la conciliación del sueño y la continuidad del sueño profundo.","intensity":15},{"key":"appetite","label":"Apetito","description":"Estimulación del hambre y de la apreciación gustativa (efecto «munchies»).","intensity":15},{"key":"uplift","label":"High","description":"Euforia e intensidad sensorial; percepción del tiempo y del espacio modificada.","intensity":20}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"controlled-named","scheduleLabel":"Estupefaciente: listado nominalmente","frScheduleStatus":"controlled-clause","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"Sustancia controlada. El ADB-CHMINACA fue objeto de una evaluación de riesgos por el EMCDDA, hoy EUDA, en 2017, en el marco del dispositivo europeo de alerta temprana, procedimiento que abre la vía a medidas de control en el conjunto de los Estados miembros. La molécula está inscrita en la lista II del Convenio de las Naciones Unidas de 1971 sobre sustancias psicotrópicas, bajo el código PC 013 de la lista verde de la JIFE, control que se impone a todos los Estados parte. No se reconoce ningún uso médico, ni en Europa ni en otros lugares.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Estupefaciente. En Francia, los cannabinoides de síntesis están clasificados como estupefacientes por el arrêté du 31 mars 2017 que modifica el arrêté du 22 février 1990, texto que inscribió doce familias genéricas y diez sustancias designadas nominalmente. El ADB-CHMINACA, indazol-3-carboxamida, entra en el ámbito de esas familias genéricas: depende por tanto de una cláusula de familia y no de la mención « tétrahydrocannabinols » del anexo IV, que contempla los ésteres y éteres del THC. Francia aplica además la lista II del Convenio de 1971 sobre sustancias psicotrópicas, en la que figura la molécula. Uso, tenencia, cesión y tráfico están prohibidos y sancionados penalmente.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Carlier J et al. Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS J, 2017.","pmid":"28070717","doi":"10.1208/s12248-016-0037-5","url":"https://pubmed.ncbi.nlm.nih.gov/28070717/"},{"label":"Adamowicz P, Gieroń J. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA. Clinical Toxicology, 2016.","pmid":"27227269","doi":"10.1080/15563650.2016.1190016","url":"https://pubmed.ncbi.nlm.nih.gov/27227269/"},{"label":"Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015). Clinical Toxicology, 2019.","pmid":"29989463","doi":"10.1080/15563650.2018.1485927","url":"https://pubmed.ncbi.nlm.nih.gov/29989463/"},{"label":"Hermanns-Clausen M et al. Acute toxicity of ADB-CHMINACA: a case series of patients with pronounced central nervous symptoms. British Journal of Clinical Pharmacology, 2026.","pmid":"41916726","doi":"10.1002/bcp.70538","url":"https://pubmed.ncbi.nlm.nih.gov/41916726/"},{"label":"Gatch MB, Forster MJ. Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats. Psychopharmacology, 2018.","pmid":"29138877","doi":"10.1007/s00213-017-4783-6","url":"https://pubmed.ncbi.nlm.nih.gov/29138877/"},{"label":"Hasegawa K et al. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. Forensic Toxicology, 2015.","pmid":"26257834","doi":"10.1007/s11419-015-0272-y","url":"https://pubmed.ncbi.nlm.nih.gov/26257834/"},{"label":"Hasegawa K et al. Identification and quantification of predominant metabolites of MAB-CHMINACA in an authentic human urine specimen. Drug Testing and Analysis, 2018.","pmid":"28560823","doi":"10.1002/dta.2220","url":"https://pubmed.ncbi.nlm.nih.gov/28560823/"},{"label":"Wouters E et al. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists. Drug Testing and Analysis, 2019.","pmid":"31021521","doi":"10.1002/dta.2607","url":"https://pubmed.ncbi.nlm.nih.gov/31021521/"},{"label":"Navarro-Tapia E et al. Detection of the Synthetic Cannabinoids AB-CHMINACA, ADB-CHMINACA, MDMB-CHMICA and 5F-MDMB-PINACA in Biological Matrices: A Systematic Review. Biology, 2022.","pmid":"35625524","doi":"10.3390/biology11050796","url":"https://pubmed.ncbi.nlm.nih.gov/35625524/"},{"label":"Filipiuc SI et al. Acute Toxicity of Three Synthetic Cannabinoids: First In Vivo Preclinical Study. Molecules, 2026.","pmid":"42451732","doi":"10.3390/molecules31132365","url":"https://pubmed.ncbi.nlm.nih.gov/42451732/"},{"label":"OICS, Liste verte : substances psychotropes sous contrôle international (ADB-CHMINACA, tableau II, code PC 013)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/en/psychotropics/green-list.html"},{"label":"OFDT, Nouveaux produits de synthèse : cadre légal français des cannabinoïdes de synthèse (arrêté du 31 mars 2017)","pmid":null,"doi":null,"url":"https://www.ofdt.fr/produits-et-addictions/de-z/nouveaux-produits-de-synthese/"}],"meta":{"slug":"adb-chminaca","url":"https://es.phytogrammes.com/wiki/adb-chminaca","lastVerified":"2026-05-01","dataUpdatedAt":"2026-07-29","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}